Shklovskaya, E.; Pedersen, B.; Stewart, A.; Simpson, J.O.G.; Ming, Z.; Irvine, M.; Scolyer, R.A.; Long, G.V.; Rizos, H.
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers. Cancers 2022, 14, 4830.
https://doi.org/10.3390/cancers14194830
AMA Style
Shklovskaya E, Pedersen B, Stewart A, Simpson JOG, Ming Z, Irvine M, Scolyer RA, Long GV, Rizos H.
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers. Cancers. 2022; 14(19):4830.
https://doi.org/10.3390/cancers14194830
Chicago/Turabian Style
Shklovskaya, Elena, Bernadette Pedersen, Ashleigh Stewart, Jack O. G. Simpson, Zizhen Ming, Mal Irvine, Richard A. Scolyer, Georgina V. Long, and Helen Rizos.
2022. "Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers" Cancers 14, no. 19: 4830.
https://doi.org/10.3390/cancers14194830
APA Style
Shklovskaya, E., Pedersen, B., Stewart, A., Simpson, J. O. G., Ming, Z., Irvine, M., Scolyer, R. A., Long, G. V., & Rizos, H.
(2022). Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers. Cancers, 14(19), 4830.
https://doi.org/10.3390/cancers14194830